| Interleukin-2 signaling | R-HSA-451927 | 5.05 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 |
| GAB1 signalosome | R-HSA-180292 | 6.31 |
| Developmental Biology | R-HSA-1266738 | 3.48 |
| Signaling by VEGF | R-HSA-194138 | 4.66 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 |
| IRS-mediated signalling | R-HSA-112399 | 4.87 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 7.81 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 9.18 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.37 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 7.37 |
| PI3K/AKT activation | R-HSA-198203 | 6.32 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 7.52 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.46 |
| Immune System | R-HSA-168256 | 2.37 |
| Frs2-mediated activation | R-HSA-170968 | 5.12 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.37 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 4.95 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.81 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 9.52 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 8.12 |
| Signaling by FGFR in disease | R-HSA-1226099 | 7.49 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.89 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.46 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| Prolonged ERK activation events | R-HSA-169893 | 5.11 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.03 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.12 |
| PI3K Cascade | R-HSA-109704 | 6.68 |
| Axon guidance | R-HSA-422475 | 3.93 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.23 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.52 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 8.98 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 8.66 |
| Signaling by Leptin | R-HSA-2586552 | 5.1 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.05 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.85 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.73 |
| Disease | R-HSA-1643685 | 3.33 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.85 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 11.4 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 9.28 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 9.4 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.4 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.37 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.37 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.59 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.98 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.89 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.56 |
| Diseases of signal transduction | R-HSA-5663202 | 4.89 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 |
| Signalling to RAS | R-HSA-167044 | 5.08 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.28 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.37 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 |
| ARMS-mediated activation | R-HSA-170984 | 5.12 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 |
| Signaling by Interleukins | R-HSA-449147 | 4.71 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.37 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 |
| SOS-mediated signalling | R-HSA-112412 | 5.15 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 |
| Adaptive Immune System | R-HSA-1280218 | 3.19 |
| MAPK family signaling cascades | R-HSA-5683057 | 4.89 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 6.37 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.43 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 8.89 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 9.4 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 9.4 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 9.4 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Signalling to ERKs | R-HSA-187687 | 5.04 |
| Signal Transduction | R-HSA-162582 | 1.78 |